Treatment Landscape for Patients with Advanced Renal Cell Carcinoma (RCC)

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial showing high accuracy for ccRCC detection.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.